**REASONS TO CONSIDER**

**High Growth Potential**
The China biotech market was valued at nearly $40bn in 2021. Forecasts suggest it could surpass $100bn by 2026, highlighting the substantial room for growth.\(^{(1)}\)

**Structural Tailwinds**
Health care expenditures in China have grown at an annualized rate of 20% since 2003.\(^{(2)}\) We believe biotech companies are well-positioned to benefit from further growth in this sector.

**Targeted Exposure**
In contrast to other funds that offer global or broader health care sector exposure, CHB specifically targets the biotech industry in China.

---

**PERFORMANCE (%)**

<table>
<thead>
<tr>
<th></th>
<th>1M</th>
<th>YTD</th>
<th>1Y</th>
<th>3Y</th>
<th>Since Inception</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAV</td>
<td>5.32%</td>
<td>-10.73%</td>
<td>-11.66%</td>
<td>-16.81%</td>
<td>-16.27%</td>
</tr>
<tr>
<td>Market Price</td>
<td>5.23%</td>
<td>-9.86%</td>
<td>-12.91%</td>
<td>-17.06%</td>
<td>-16.45%</td>
</tr>
<tr>
<td>Index</td>
<td>5.38%</td>
<td>-10.13%</td>
<td>-11.00%</td>
<td>-16.24%</td>
<td>-15.69%</td>
</tr>
</tbody>
</table>

The performance data quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance quoted. High short-term performance, when observed, is unusual and investors should not expect such performance to be repeated. Returns for periods greater than one year are annualized. Click here for standard performance as of the most recent quarter-end.

**INDUSTRY BREAKDOWN (%)**

- Biotechnology: 57.20%
- Pharmaceuticals: 23.98%
- Life Sciences Tools & Services: 13.11%
- Commodity Chemicals: 2.08%
- Health Care Equipment: 2.01%
- Fertilizers & Agricultural Chemicals: 0.76%
- Health Care Supplies: 0.52%
- Packaged Foods & Meats: 0.32%

All Sector, Industry and Geographic breakdowns, where provided, are based on equity positions held by the ETF and exclude cash, currencies, and other holdings.

---

**TOP 10 HOLDINGS (%)**

<table>
<thead>
<tr>
<th>Holdings Subject to Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Changqing Zhif-a: 8.53%</td>
</tr>
<tr>
<td>Cspc Pharmaceuticals: 8.34%</td>
</tr>
<tr>
<td>Changchun High-a: 8.32%</td>
</tr>
<tr>
<td>Wuxi Biologics Cayman Inc: 6.75%</td>
</tr>
<tr>
<td>Walvax Biotechnology Co-a: 6.26%</td>
</tr>
<tr>
<td>Beijing Tian-a: 4.92%</td>
</tr>
<tr>
<td>Shanghai Raas-a: 4.91%</td>
</tr>
<tr>
<td>Sichuan Kelun-a: 4.51%</td>
</tr>
<tr>
<td>Hualan Biologix-a: 4.32%</td>
</tr>
<tr>
<td>Genscript Biotech Corp: 4.17%</td>
</tr>
</tbody>
</table>

---

**ETF Category: International Access – China Sector**

**Inception Date**: 09/22/2020

**Underlying Index**: Solactive China Biotech Innovation Index

**Number of Holdings**: 44

**Assets Under Management**: $2.30 mil

**Total Expense Ratio**: 0.65%

**Distribution Frequency**: Semi-Annually

**TICKER**: CHB

**CUSIP**: 37954Y251

**Exchange**: NASDAQ

**Bloomberg IOPV Ticker**: CHBIV

**Index Ticker**: SOLCHB

---

**ETF Category: International Access – China Sector**

**As of 11/30/2023**

---

**KEY INFORMATION**

**Inception Date**: 09/22/2020

**Underlying Index**: Solactive China Biotech Innovation Index

**Number of Holdings**: 44

**Assets Under Management**: $2.30 mil

**Total Expense Ratio**: 0.65%

**Distribution Frequency**: Semi-Annually
DEFINITIONS

The Solactive China Biotechnology Innovation Index is designed to provide exposure to exchange-listed companies that are directly involved in China's biotechnology industry. In constructing the index, the Solactive utilizes FactSet Industry classifications to identify companies that are directly involved in the biotechnology industry. Only those securities classified in the biotechnology industry according to FactSet as of each rebalance date are eligible for inclusion in the index. The index is weighted according to a modified capitalization weighting methodology and is reconstituted and re-weighted semi-annually.

(1) Research and Markets, Oct 2022
(2) Council on Foreign Relations, May 2021

Investing involves risk, including the possible loss of principal. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles, or from economic or political instability in other nations. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Investments in securities in the Biotechnology and Health Care sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. Technology companies and companies that rely heavily on technology tend to be more volatile than the overall market, and are also heavily dependent on patent and intellectual property rights. Securities focusing on a single country and narrowly focused investments may be subject to higher volatility. CHB is non-diversified. The information provided is not intended for trading purposes, and should not be considered investment advice.

Carefully consider the Fund’s investment objectives, risk factors, charges, and expenses before investing. This and additional information can be found in the Fund’s full or summary prospectus, which may be obtained by calling 1.888.493.8631, or by visiting globalxetfs.com. Please read the prospectus carefully before investing.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer ("NBBO") as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares did not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Global X Management Company LLC serves as an advisor to the Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO, 1 Freedom Valley Drive, Oaks, PA, 19456), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.